FDA Authorizes APP to Reintroduce Fresenius Propoven 1% to Help Ease U.S. Propofol Shortage

The U.S. Food and Drug Administration has authorized drug maker APP to reintroduce Fresenius Propoven 1% (1 percent propofol) to the U.S. market in order to help ease the ongoing propofol injection shortage, according to a letter from APP.

Advertisement

APP, in conjunction with the FDA, began importing Fresenius Propoven 1% in late 2009 but stopped in Feb. 2010 when the initial supply ran out, according to the letter.

Effective immediate, APP, which is the only company authorized to import Fresenius Propoven 1%, will begin importing the following products:

  • DIPRIVAN (20-mL, 50-MI and 100-mL vials)
  • APP Propofol 1% (20-mL, 50-MI and 100-mL vials)
  • Fresenius Propoven 1% (20-mL, 50-MI and 100-mL vials)

The letter also notes some important difference between U.S.-manufactured propofol and international Fresenius Propoven 1%, including contraindication in patients with peanut and soy allergies. For complete information on the difference, please refer to the APP’s letter.

Read APP’s letter on Fresenius Propoven 1% (pdf).

Advertisement

Next Up in Anesthesia

Advertisement

Comments are closed.